8-K: Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study

Cellectar Biosciences announced positive results from its CLOVER WaM pivotal study, with iopofosine I 131 demonstrating an 80% overall response rate and a 56.4% major response rate in relapsed/refractory Waldenstrom's macroglobulinemia patients, exceeding the primary endpoint.

Summary

• Cellectar Biosciences reported positive results from its CLOVER WaM pivotal study for iopofosine I 131 in patients with relapsed/refractory Waldenstrom's macroglobulinemia (WM).
• The study achieved an 80% overall response rate (ORR) and a 56.4% major response rate (MRR), surpassing the 20% MRR primary endpoint.
• The study included 55 patients with a median age of 70 years and a median of 4 prior lines of therapy.
• Approximately 27% of patients were refractory to all available therapies, and 40% were dual-class refractory.
• The disease control rate was 98.2%, and the median duration of response was not reached, with 78% of major responders and 72% of overall responders remaining progression-free at 18 months.
• The company plans to submit a New Drug Application (NDA) in the fourth quarter of 2024 and seek priority review.

Sentiment

Score: 9

Explanation: The document presents very positive clinical trial results, exceeding the primary endpoint and showing durable responses with a manageable safety profile. The company's plan to submit an NDA and seek priority review further enhances the positive outlook.

Positives

• Iopofosine I 131 demonstrated a high overall response rate of 80% and a major response rate of 56.4%, exceeding the primary endpoint of 20%.
• The drug showed a 98.2% disease control rate in heavily pretreated patients.
• The duration of response was durable, with 78% of major responders and 72% of overall responders remaining progression-free at 18 months.
• The treatment was well-tolerated, with a safety profile consistent with previous reports and no cardiovascular, renal, or liver toxicities.
• The study showed consistent response rates across various difficult-to-treat subgroups, including those with MYD88-wt, P53-mutated, and post-BTKi refractory disease.
• The company is planning to submit an NDA in the fourth quarter of 2024 and seek priority review, potentially accelerating the drug's availability.

Negatives

• The preliminary cash and cash equivalents of approximately $25.9 million as of June 30, 2024, are subject to change and may differ materially from the final figures.
• The most commonly reported treatment emergent adverse events were hematologic in nature (thrombocytopenia, neutropenia and anemia), although these were predictable and manageable.

Risks

• The preliminary cash and cash equivalents figure is subject to change and may differ materially from the final amount.
• The company faces risks related to raising additional capital, disruptions at their sole source supplier of iopofosine, and the ability to attract and retain partners.
• There are uncertainties related to the FDA review process and the potential for competition from other pharmaceutical companies.
• The company's ability to maintain orphan drug designation for iopofosine and the volatile market for priority review vouchers are also risks.
• The company's pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates is also a risk.

Future Outlook

The company plans to submit a New Drug Application (NDA) for iopofosine I 131 in the fourth quarter of 2024 and will be seeking priority review, which provides an estimated six-month regulatory review period. They believe iopofosine I 131 has the potential to become the standard-of-care therapy for relapsed/refractory patients.

Management Comments

• Sikander Ailawadhi, M.D., stated that treatment options for relapsed or refractory WM patients are limited and there is a critical need for new therapies.
• James Caruso, president and CEO of Cellectar, stated that the outcomes observed in the study far exceed expectations and provide evidence of the potential for iopofosine in a broad range of WM patients.
• James Caruso also stated that they believe iopofosine I 131 has the potential to become the standard-of-care therapy for relapsed/refractory patients.

Industry Context

The announcement is significant as it addresses the unmet need for effective treatments for relapsed/refractory Waldenstrom's macroglobulinemia, a rare blood cancer. Current treatment options are limited, and the positive results from the CLOVER WaM study position iopofosine I 131 as a potential first-in-class therapy in this space.

Comparison to Industry Standards

• The study's 80% overall response rate (ORR) and 56.4% major response rate (MRR) are significantly higher than the typical 10% response rate seen with salvage therapies in later lines of treatment for WM.
• The median duration of response (DoR) not being reached, with 78% of major responders and 72% of overall responders remaining progression-free at 18 months, is a substantial improvement over the less than six-month durability often seen with current treatments.
• The study included a heavily pretreated patient population, with 27% refractory to all available therapies and 40% dual-class refractory, making the results even more compelling compared to studies with less refractory patient groups.
• The lack of cardiovascular, renal, or liver toxicities, and no peripheral neuropathy or significant bleeding, is a notable advantage over many other cancer therapies, including BTKi inhibitors which are a common treatment for WM.
• The results are particularly impressive when compared to the current standard of care, where BTKi therapies do not demonstrate complete response rates and require continuous treatment, while iopofosine I 131 is a time-limited treatment.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results and the potential for a new treatment option.
• Patients with relapsed/refractory Waldenstrom's macroglobulinemia may benefit from a new, effective treatment option.
• Employees may be positively impacted by the company's progress and potential for growth.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The company plans to submit a New Drug Application (NDA) in the fourth quarter of 2024.
• The company will seek priority review for the NDA, which provides an estimated six-month regulatory review period.
• The company will host a conference call and webcast on July 24, 2024, to discuss the CLOVER WaM study data.

Key Dates

Keywords

Waldenstrom's macroglobulinemia, Iopofosine I 131, CLOVER WaM study, Overall response rate, Major response rate, Radiotherapeutic, BTKi, Cancer treatment, PDC, NDA